contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


asarina-pharma-ab-announces-new-date-for-the-release-of-annual-report-for-2023

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Asarina Pharma

Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to 28 May 2024.The previously communicated release date...

<div class="mfn-preamble"><p><strong>Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to 28 May 2024.</strong></p></div><div class="mfn-body"><p>The previously communicated release date was 23 May 2024. The reason for the postponement is that the final phase of the preparation of the Annual Report is taking longer than expected.</p><p>For additional information, please contact:</p><p>Jakob Dynnes Hansen, CFO, Asarina Pharma AB<br>Telefon: +45 5132 3698<br>E-post: jakob.dynnes@asarinapharma.com</p><p>The Company’s Certified Adviser is Carnegie Investment Bank AB (publ).</p></div><div class="mfn-footer mfn-contacts mfn-c85405f73fa6"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Peter Nordkild, CEO, Asarina Pharma AB<br>Phone: +45 25 47 16 46<br>E-mail: <a rel="noopener" href="mailto:peter.nordkild@asarinapharma.com">peter.nordkild@asarinapharma.com</a></p><p>Jakob Dynnes Hansen, CFO, Asarina Pharma AB<br>Tel: +45 5132 3698<br>E-mail: <a rel="noopener" href="mailto:jakob.dynnes@asarinapharma.com">jakob.dynnes@asarinapharma.com</a></p><p>The Company’s Certified Adviser is Carnegie Investment Bank AB (publ)</p></div><div class="mfn-footer mfn-about mfn-6229831054f8"><p><strong class="mfn-heading-1">About Asarina Pharma</strong><br>Asarina Pharma is a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/8bec9f42-6d67-4b9b-b53d-ad14842b76f9/asarina-pharma-ab-announces-new-date-for-the-release-of-annual-report-for-2023.pdf" class="mfn-generated mfn-primary">Asarina Pharma AB announces new date for the release of Annual Report for 2023</a></p></div>

Asarina Pharma AB announces new date for the release of Annual Report for 2023

Return on capital (ROE, ROI, ROIC, RONIC)

What does negative working capital mean and why is it a good thing?

Drug development investment: Value creation through M&As and licensing agreements

Income statement

Amazon continues to grow in Sweden

Stay up to date with our newsletter